Last update April 27, 2024

Irbesartan

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Irbesartan is an angiotensin II receptor antagonist with actions similar to those of losartan. It is indicated in the treatment of hypertension. Oral administration once a day. 

At the time of the last update, we found no published data on its excretion in breast milk. 

Its high binding to plasma proteins and large volume of distribution make it unlikely to be excreted in milk. 

It is one of the sartanes (ARA-II) with the longest half-life and oral bioavailability (Tamargo 2006), so it would be one of the least indicated during lactation. 

Until more data on this drug are known, safer alternatives are preferable (Rowe 2013), especially in the neonatal period and in case of prematurity.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Irbesartan in other languages or writings:

Groups

Irbesartan belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Irbesartan in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 60 - 80 %
Molecular weight 429 daltons
Protein Binding 96 %
VD 0.7 - 1.3 l/Kg
pKa 5.85 -
Tmax 1.5 - 2 hours
T½ 12 - 17 hours

References

  1. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr Clin North Am. 2013 Feb;60(1):275-94. Abstract
  2. Sano.Ave. Irbesartan. Drug Summary. 2012 Full text (in our servers)
  3. AEMPS. Irbesartán. Ficha técnica. 2008 Full text (in our servers)
  4. Tamargo j, Caballero R, Gómez R, Núñez L, Vaquero M y Delpón E. Características farmacológicas de los ARA-II. ¿Son todos iguales?. Rev Esp Cardiol Supl. 2006;6:10C-24C. 2006 Full text (in our servers)

Total visits

24,396

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Amamanta of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM